Indicaciones e interpretación de los estudios analíticos hormonales de la corteza suprarrenal

  1. Marta Araujo Castro 1
  2. Eider Pascual Corrales 1
  3. Andrés Ortiz Flores 2
  4. Héctor Francisco Escobar Morreale 3
  1. 1 Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal e Instituto Ramón y Cajal de Investigación Biomédica (IRYCIS), Madrid, España
  2. 2 Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal e Instituto Ramón y Cajal de Investigación Biomédica (IRYCIS), Madrid, España Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, España
  3. 3 Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal e Instituto Ramón y Cajal de Investigación Biomédica (IRYCIS), Madrid, España Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, España Facultad de Medicina, Universidad de Alcalá, Alcalá de Henares Madrid, España
Aldizkaria:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Argitalpen urtea: 2024

Zenbakien izenburua: Enfermedades endocrinológicas y metabólicas (I) Patología suprarrenal

Saila: 14

Zenbakia: 13

Orrialdeak: 754-758

Mota: Artikulua

DOI: 10.1016/J.MED.2024.06.015 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Medicine: Programa de Formación Médica Continuada Acreditado

Laburpena

In the adrenal cortex, entities ranging from benign diseases such as adrenocortical adenomas to malignant diseases such as adrenocortical carcinoma or adrenal metastases can be found. Regarding functionality, the spectrum of diseases varies widely: from non-functioning adenomas, patients with autonomous cortisol secretion (ACS), primary hyperaldosteronism (PHA), ACTH-independent Cushing's syndrome, excess secretion of sex hormones, congenital adrenal hyperplasia (CAH), and adrenal insufficiency (AI). A hormonal study is essential for the proper characterization of these disorders. Baseline hormonal tests and functional studies are both necessary in some cases to reach the definitive diagnosis. The test of choice for Cushing's syndrome screening is urinary free cortisol, late-night salivary cortisol, or a 1 mg dexamethasone suppression test (DST). For ACS, it is a DST. For PAH, it is calculation of the plasma aldosterone concentration and renin activity or concentration ratio. For AI, it is the determination of plasma cortisol between 8:00 and 9:00 a.m. and after cosyntropin stimulation. Lastly, for CAH, it is the measurement of plasma 17-hydroxyprogesterone.

Erreferentzia bibliografikoak

  • 1. M. Araujo-Castro et al. Possible, probable, and certain hypercortisolism: A continuum in the risk of comorbidity Ann Endocrinol (Paris). (2023)
  • 2. M. Fassnacht et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors Eur J Endocrinol. (2023)
  • 3. L.K. Nieman et al. The diagnosis of Cushing's syndrome: An endocrine society clinical practice guideline J Clin Endocrinol Metab. (2008)
  • 4. M. Araujo-Castro et al. Autonomous cortisol secretion in adrenal incidentalomas Endocrine. (2019)